@article{2103eb5f3aff42a78400a107fef5faf6,
title = "Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens",
abstract = "For young adults with acute lymphoblastic leukemia, pediatric-based regimens are likely to provide the following when compared to hyper-CVAD regimens: better disease control, less hospitalization time, diminished acute toxicities, decreased financial cost, more quality-adjusted life years, and fewer adverse late effects, such as infertility, myelodysplasia, and second malignant neoplasms. There are also reasons to expect less cardiac and cognitive dysfunction after pediatric regimens. The improved quality and quantity of life associated with pediatric regimens renders them preferable to hyper-CVAD regimens for the treatment of Philadelphia-negative B-precursor or T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma in young adults.",
author = "Siegel, {Stuart E.} and Anjali Advani and Nita Seibel and Lori Muffly and Wendy Stock and Selina Luger and Bijal Shah and DeAngelo, {Daniel J.} and Freyer, {David R.} and Dan Douer and Johnson, {Rebecca H.} and Brandon Hayes-Lattin and Mark Lewis and Jaboin, {Jerry J.} and Coccia, {Peter F.} and Archie Bleyer",
note = "Funding Information: Drs. Muffly has research support from Shire Pharmaceuticals. Dr. Advani has research support and honoraria from Pfizer and Amgen, and prior consulting remuneration from Jazz and Sigma-Tau Pharmaceuticals. Dr. Johnson serves as a consultant and on the speaker bureau of Shire Pharmaceuticals and Jazz Pharmaceuticals, which produce asparaginase products. Dr. DeAngelo received funding from Shire Pharmaceuticals. Dr. Douer had served as consultant to Shire Pharmaceuticals. Dr. Hayes-Lattin was on a speaker's bureau for Sigma-Tau Pharmaceuticals. Dr. Shah has research grant support from Incyte, Rosetta Genomics, and the DeBartolo institute for Personalized Medicine and has received reimbursement from Amgen, Baxalta, Bayer, Celgene, Clonoseq, Jazz and Pfizer pharmaceutical companies. Dr. Bleyer served as a consultant to Enzon and Sigma-Tau Pharmaceuticals when they had an asparaginase product, which is one of the agents included in this review. The following (in alphabetical order) are not aware of any conflicts of interest with the contents or messaging of the manuscript: Drs. Coccia, Freyer, Jaboin, Lewis, Reed, Siegel. Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2018",
month = oct,
doi = "10.1002/ajh.25229",
language = "English (US)",
volume = "93",
pages = "1254--1266",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "10",
}